Phathom Pharmaceuticals Inc.

06/16/2025 | Press release | Distributed by Public on 06/16/2025 06:06

Material Event (Form 8-K)

Item 8.01

Other Events.

On June 16, 2025, Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company"), announced that the U.S. Food and Drug Administration ("FDA") has updated the Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") to accurately reflect the full 10-yearperiod of non-patentNew Chemical Entity ("NCE") exclusivity for VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets. The corrected Orange Book listing confirms that VOQUEZNA is entitled to NCE regulatory exclusivity through May 3, 2032, aligning with statutory requirements and reinforcing the long-term commercial runway for the first-in-classproduct.

Phathom Pharmaceuticals Inc. published this content on June 16, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 16, 2025 at 12:06 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io